Phoslo: Advanced Phosphate Control for Renal Health
| Product dosage: 667mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.41 | $48.25 (0%) | 🛒 Add to cart |
| 30 | $1.74 | $72.37 $52.27 (28%) | 🛒 Add to cart |
| 60 | $1.07 | $144.74 $64.33 (56%) | 🛒 Add to cart |
| 90 | $0.85 | $217.11 $76.39 (65%) | 🛒 Add to cart |
| 120 | $0.74 | $289.48 $88.45 (69%) | 🛒 Add to cart |
| 180 | $0.63 | $434.23 $112.58 (74%) | 🛒 Add to cart |
| 270 | $0.61 | $651.34 $164.85 (75%) | 🛒 Add to cart |
| 360 | $0.61
Best per pill | $868.45 $218.12 (75%) | 🛒 Add to cart |
Synonyms | |||
Phoslo (calcium acetate) is a clinically proven phosphate binder specifically formulated for patients with end-stage renal disease (ESRD) who are on dialysis. It effectively reduces serum phosphate levels by binding dietary phosphorus in the digestive tract, preventing its absorption into the bloodstream. By maintaining optimal phosphate balance, Phoslo helps mitigate the risk of serious complications associated with hyperphosphatemia, including cardiovascular calcification and secondary hyperparathyroidism. Its targeted mechanism supports long-term renal management strategies, making it a cornerstone therapy in nephrology care for improved patient outcomes and quality of life.
Features
- Contains calcium acetate as the active ingredient
- Available in 667 mg tablets for precise dosing
- Designed to bind dietary phosphate in the gastrointestinal tract
- Formulated for easy administration with meals
- Manufactured under strict pharmaceutical quality standards
Benefits
- Effectively lowers and controls serum phosphate levels in dialysis patients
- Reduces the risk of harmful calcium-phosphate deposits in tissues and blood vessels
- Helps prevent or manage secondary hyperparathyroidism
- Supports long-term cardiovascular health by minimizing vascular calcification
- Contributes to improved bone mineral metabolism in chronic kidney disease
- Enhances overall treatment adherence through convenient dosing with meals
Common use
Phoslo is primarily indicated for the control of hyperphosphatemia in patients with end-stage renal disease. It is routinely prescribed for individuals undergoing hemodialysis or peritoneal dialysis who cannot adequately regulate phosphate levels through dietary management alone. The medication works locally in the gut by binding to dietary phosphate from food, forming insoluble calcium phosphate complexes that are excreted in feces rather than absorbed into circulation. This mechanism makes it particularly valuable for patients who require continuous phosphate management to prevent the serious sequelae of elevated phosphorus levels.
Dosage and direction
The dosage of Phoslo must be individualized based on serum phosphate levels and should be titrated to bring phosphate levels within the target range of 3.5-5.5 mg/dL. The typical initial dose for adults is 2 tablets (1334 mg) with each meal, which may be adjusted as necessary based on weekly phosphate monitoring. Tablets should be taken with meals or immediately following food intake to maximize phosphate-binding efficacy. Tablets should be swallowed whole and not crushed or chewed. Dosage adjustments should be made gradually in increments of 1-2 tablets per meal under close medical supervision, with regular monitoring of both serum phosphate and calcium levels to avoid hypercalcemia.
Precautions
Patients should have serum calcium levels monitored regularly, preferably weekly, especially during dose titration. Those with conditions that predispose to hypercalcemia (such as sarcoidosis) require particularly careful monitoring. Phoslo should be used with caution in patients with digitalis toxicity due to potential synergistic effects on cardiac rhythm. Patients should be advised to avoid concurrent use of calcium supplements unless specifically directed by their nephrologist. Those with hypophosphatemia should not use Phoslo, as it may further lower phosphate levels to dangerous degrees. Special consideration is needed for patients with gastrointestinal conditions that might affect absorption.
Contraindications
Phoslo is contraindicated in patients with hypercalcemia (serum calcium >10.5 mg/dL). It should not be used by patients with known hypersensitivity to calcium acetate or any component of the formulation. The medication is contraindicated in patients with hypophosphatemia or those who show evidence of calcium-based renal calculi. Patients with acute pancreatitis or severe digestive disorders that might impair medication absorption or excretion should avoid Phoslo. Concomitant use with other calcium-containing phosphate binders is contraindicated due to additive effects.
Possible side effects
The most common adverse reactions involve gastrointestinal disturbances, including nausea (occurring in approximately 5-10% of patients), vomiting, constipation, and diarrhea. Hypercalcemia may develop, particularly with higher doses or impaired renal function, manifesting as confusion, lethargy, nausea, vomiting, or constipation. Less frequently, patients may experience pruritus, dry mouth, or loss of appetite. Cases of ectopic calcification have been reported with prolonged hypercalcemia. Mild edema and metabolic alkalosis may occur in some patients. These side effects are generally dose-dependent and often manageable with dosage adjustment.
Drug interaction
Phoslo may decrease the absorption of tetracycline antibiotics, quinolones, iron preparations, and thyroid medications when administered concurrently—separate administration by at least 2 hours. Concurrent use with digitalis glycosides may potentiate digitalis toxicity and require more frequent monitoring. Calcium-containing preparations may enhance the effects of calcium channel blockers. The medication may interfere with the absorption of zinc and other minerals. Corticosteroids may enhance calcium absorption, potentially increasing the risk of hypercalcemia. Antacids containing magnesium should be used with caution due to potential magnesium accumulation in renal failure.
Missed dose
If a dose is missed, the patient should take it as soon as remembered with food, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistency with meal-time dosing is important for optimal phosphate control, so patients should establish routines to maintain regular dosing. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy and possibly checking serum phosphate levels.
Overdose
Overdose may lead to severe hypercalcemia, manifested by nausea, vomiting, anorexia, constipation, dry mouth, thirst, polyuria, lethargy, hypercalciuria, and metastatic calcification. In severe cases, confusion, delirium, stupor, coma, and cardiac arrhythmias may develop. Treatment involves immediate discontinuation of Phoslo, low-calcium diet, and hydration with saline diuresis. Severe hypercalcemia (serum calcium >14 mg/dL) may require hospitalization for intravenous hydration, loop diuretics, corticosteroids, or bisphosphonate therapy. Dialysis against a low-calcium bath may be necessary in patients with renal failure. Serum calcium and phosphate should be monitored frequently until levels normalize.
Storage
Store at controlled room temperature between 20°-25°C (68°-77°F), with excursions permitted between 15°-30°C (59°-86°F). Keep the container tightly closed and protect from moisture and light. Store in the original container with the desiccant canister provided. Keep out of reach of children and pets. Do not transfer tablets to other containers that lack moisture protection. Do not use if the blister pack is damaged or tablets show signs of moisture exposure. Proper storage ensures stability and efficacy throughout the shelf life. Discard any expired medication according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient needs may vary, and healthcare professionals should exercise their clinical judgment when prescribing Phoslo. The prescribing information provided here is not exhaustive—please consult the full prescribing information and clinical guidelines before initiating therapy. Treatment decisions should be based on individual patient assessment, including laboratory values, clinical status, and concomitant medications. The manufacturer’s latest prescribing information should always be consulted for the most current data.
Reviews
Clinical studies demonstrate that Phoslo effectively reduces serum phosphate levels to target ranges in approximately 65-75% of dialysis patients when used as directed. Nephrologists report satisfactory phosphate control with appropriate dosing adjustments. Patients generally tolerate the medication well, though gastrointestinal side effects remain the most common reason for discontinuation. Long-term studies show maintained efficacy with consistent use, though some patients may require combination therapy with other phosphate binders for optimal control. Real-world evidence supports its position as a first-line therapy for hyperphosphatemia management in ESRD patients.